Skip to content
Review

Mechanism and clinical relevance of metabolic-immune cross-talk in pancreatic tumor microenvironment.

Sep 2026 · Cytokine & growth factor reviews · Vol 92, pp. 101525 · 0 citations · 208 references
Medicine

TL;DR

The intricate metabolic-immune crosstalk that impacts the metabolic fitness and effector functions of infiltrating immune cells, including cytotoxic T cells, NK cells, and myeloid cells that bridge innate and adaptive immunity are explored.

Abstract

Metabolic stress-induced immunosuppression begins as early as the precancerous stage in pancreatic ductal adenocarcinoma (PDAC), increases with disease progression, and is characterized by the abundant suppressive myeloid and lymphoid cells. Metabolic adaptation and reprogramming are critical for the survival and function of tumor-infiltrating immune cells. In particular, cytotoxic T cells and natural killer (NK) cells, the stalwarts of cell-mediated immunity, often fail to adapt to the metabolically distinct pancreatic tumor microenvironment (TME) and thus perform antitumor activities poorly, leading to immune exhaustion, aggressive disease progression, metastasis, and poor immunotherapy outcomes. This review article explores the intricate metabolic-immune crosstalk, mediated by tumor microenvironment-associated factors, that impacts the metabolic fitness and effector functions of infiltrating immune cells, including cytotoxic T cells, NK cells, and myeloid cells that bridge innate and adaptive immunity. In addition, we discuss how genetic, molecular, and stromal factors drive metabolic alterations in nutrient-deficient pancreatic tumors, leading to immune cell dysfunction, impaired cytokine release, and poor antitumor immunity. This review further emphasizes the selective targeting of metabolic stress-driven immunosuppressive pathways, unresolved questions, and future directions, including how spatial nutrient gradients across the TME shape distinct regional immune phenotypes, how metabolic interactions with tumor and immune cells occur, and how tumor-selective metabolic therapies could be engineered to exploit features such as hypoxia and acidosis. Understanding these metabolic interactions is crucial for advancing personalized immunotherapy approaches, including immune checkpoint blockade therapies, CAR-T, and other adoptive immune cell therapies, which could improve clinical outcomes in PDAC patients.

View source

Similar papers

Review Open access Sep 2026

Metabolic Reprogramming in Gastric Cancer Immunity Mechanisms and Therapeutic Implications

The metabolic supply-demand mismatch explains why certain interventions can revive effector cells while potentially harming other cell types, and the need for spatially resolved metabolic profiling, biomarker-driven patient stratification, and personalized therapies to overcome metabolic immunosuppression and improve c...

Xiang-Yang Wang, Ying Wu, Yu-Tong Fu et al. · 0 citations
Review Open access Sep 2026

B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance

This review focuses on the intersection of B cell biology and tumor immunometabolism, emphasizing how hypoxia, lactate, nutrient limitation, adenosine, PGE2, kynurenine and B cell-derived γ-aminobutyric acid (GABA) may shape B cell states and their interactions with myeloid and lymphoid cells.

Swati Gupta, Sandip Rath, Surathi Maiti et al. · 0 citations
Review Open access Sep 2026

Innate immunity-stroma crosstalk in pancreatic cancer: overcoming spatial and metabolic barriers to immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to current immunotherapies, a challenge largely attributed to its uniquely immunosuppressive and desmoplastic tumor microenvironment (TME). At the heart of this therapeutic recalcitrance lies the dynamic, bidirectional crosstalk between innate immun...

Yu-Long Hou, Zhen-Hua Tan · 0 citations
Review Open access Aug 2026

Immune modulation in gastric cancer: from macrophage polarization to immunotherapy

This review synthesizes newly emerging mechanisms of TAM-mediated immunotherapy resistance, including spatial heterogeneity, stromal-vascular remodeling, and exosomal crosstalk, with the latest clinical advances in macrophage-directed immunotherapies.

Xiao-Feng Cui, Xue-Rui Wang, Nan Jiang et al. · 0 citations
Review Open access Aug 2026

The Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment and the Mechanism of Immune Therapy Resistance

The article further explores therapeutic strategies targeting metabolic nodes such as lactate dehydrogenase A, CD73/CD39 - adenosine axis, to reverse immunosuppression and enhance the efficacy of ICIs, and looks forward to the future direction of using "metabolism-immunity" typing to guide individualized combination th...

Gan-Yu Yi · 0 citations
Review Open access Sep 2026

Exosome-mediated metabolic-immune regulatory axis: mechanisms of gastric cancer progression and resistance and targeting strategies

Gastric cancer (GC) is characterized by marked heterogeneity and frequent resistance to chemotherapy and immunotherapy. Exosomes mediate intercellular communication between tumor, stromal, and immune cells and may couple metabolic adaptation to immune suppression. This review synthesizes evidence for a bidirectional ex...

Shun Yao, Hong-Yu Chai, Lu-Lu Tang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.